Clinician's Manual on Myelodysplastic Syndromes - A. List (GMG, 2008) WW.pdf

(1565 KB) Pobierz

Clinician’s Manual on

Myelodysplastic Syndromes

This reprint may contain information regarding use of a drug(s) that is not consistent with

the product labeling as approved by the Food and Drug Administration. Celgene may have

supplied study drug and certain authors may have acted as consultants to Celgene within

the last year. Please see accompanying full Prescribing Information and if applicable the

FDA-approved Medication Guide.

REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-

dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes

associated with a deletion 5q cytogenetic abnormality, with or without additional

cytogenetic abnormalities.

VIDAZA is indicated for treatment of patients with the following myelodysplastic syndrome

subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied

by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia

with excess blasts, refractory anemia with excess blasts in transformation, and chronic

myelomonocytic leukemia.

Clinician’s Manual on

Myelodysplastic Syndromes

Alan List

Executive Vice President, Physician-in-Chief

H. Lee Moffitt Cancer Center & Research Institute

Tampa, FL

Published by Current Medicine Group, 236 Gray’s Inn Road, London, UK

www.currentmedicinegroup.com

Reprinted 2009, 2010

or transmitted in any form or by any means electronic, mechanical, photocopying, recording or

otherwise without the prior written permission of the copyright holder.

British Library Cataloguing-in-Publication Data.

A catalogue record for this book is available from the British Library.

ISBN: 978-1-85873-427-9

Although every effort has been made to ensure that drug doses and other information are presented

accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither

the publisher nor the authors can be held responsible for errors or for any consequences arising from

the use of the information contained herein. Any product mentioned in this publication should be

used in accordance with the prescribing information prepared by the manufacturers. No claims or

endorsements are made for any drug or compound at present under clinical investigation.

Project editor: Nadine Lemmens

Designer: Joe Harvey

Production: Marina Maher

Printed in Canada by Allprint